Johnson & Johnson: Renal Insufficiency trials

The registry lists 27 Renal Insufficiency studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 2 have results posted.

Phase 1 14Phase 2 2Phase 3 6Phase 4 3No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal ImpairmentCompletedNCT01064414Phase 3Results posted
• Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMACTerminatedNCT00338455Phase 2Results posted
• A Study of JNJ-73763989 in Adult Participants With Renal ImpairmentCompletedNCT04963738Phase 1
• A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult ParticipantsCompletedNCT04616677Phase 1
• A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult ParticipantsTerminatedNCT04474210Phase 1
• A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult ParticipantsTerminatedNCT04426357Phase 1
• A Study of Orally Administered Pimodivir in Adult Participants With Renal ImpairmentTerminatedNCT03947814Phase 1
• A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal FunctionCompletedNCT03546205Phase 1
• A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Participants With Various Degrees of Renal FunctionCompletedNCT03189498Phase 1
• A Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of OdalasvirCompletedNCT02961660Phase 1
• A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335CompletedNCT02894905Phase 1
• A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered EsketamineCompletedNCT02606084Phase 1
• An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.WithdrawnNCT02397395Phase 2
• A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney FunctionCompletedNCT01759576Phase 1
• A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal FunctionCompletedNCT01715259Phase 1
• A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney FunctionCompletedNCT01309438Phase 1
• A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal FunctionCompletedNCT00791401Phase 1
• An Efficacy and Safety Study for Nesiritide in Heart Failure Patients With Reduced Kidney Function Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (CPB Pump or Heart Lung Machine)WithdrawnNCT00530361Phase 3
• The Effect of Epoetin Alfa on Cardiac Function and Quality of Life in Patients With Early Renal ((Kidney) DiseaseCompletedNCT00446576Phase 3
• Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney FailureCompletedNCT00391287
• A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects.CompletedNCT00364260Phase 3
• EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal FailureCompletedNCT00338000Phase 4
• Effects of Early Correction of Anemia in Patients With Chronic Renal InsufficiencyTerminatedNCT00312871Phase 4
• A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care TherapyCompletedNCT00270387Phase 3
• A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis PatientsCompletedNCT00261521Phase 3
• Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)TerminatedNCT00211120Phase 4
• Study to Monitor the Incidence of Pure Red Cell Aplasia (PRCA) and/or Antibodies to Erythropoietin Among Participants Receiving Epoetin Alfa or Another ErythropoietinCompletedNCT00210951